Abstract: A method for producing 225A including: a method (X) for purifying a 226Ra-containing solution, including an adsorption step of allowing a 226Ra ion to adsorb onto a carrier having a function of selectively adsorbing a divalent cation by bringing a 226Ra-containing solution into contact with the carrier under an alkaline condition, and an elution step of eluting the 226Ra ion from the carrier under an acidic condition; a method for producing a 226Ra target, including an electrodeposition liquid preparation step of preparing an electrodeposition liquid by using a purified 226Ra-containing solution obtained by the method (X), and an electrodeposition step of electrodepositing a 226Ra-containing substance on a substrate by using the electrodeposition liquid; and a step of irradiating a 226Ra target produced by the method for producing a 226Ra target with at least one selected from a charged particle, a photon, and a neutron by using an accelerator.

Abstract: A method for producing an 225Ac solution includes a step (I) of irradiating a 226Ra target with particles to generate two or more actinium radioisotopes (Ac) including at least 225Ac, a step (II) of dissolving the 226Ra target after the aforementioned step to obtain a solution (1), a step (III) of separating 226Ra and Ac contained in the solution (1) to obtain a solution (2), a step (IV) of allowing Ac contained in the solution (2) other than 225Ac to decay to obtain a solution (3), and a step (V) of separating Ra and Ac contained in the solution (3) to obtain a solution (4). The solution (4) is used to produce a medicine that contains, as an active ingredient, a conjugate between a chelating agent that has formed a complex with 225Ac, and a targeting agent.

Abstract: An object of the present invention is to provide a method for purifying efficiently and easily a 226Ra-containing solution obtained when 225Ac is produced from a 226Ra target, a method for producing a 226Ra target by using the purified 226Ra-containing solution obtained by the above purification method, and a method for producing 225Ac including these above methods. The method for purifying a 226Ra-containing solution according to the present invention is characterized by including an adsorption step (R1) of allowing 226Ra ions to adsorb onto a carrier having a function of selectively adsorbing divalent cations by bringing a 226Ra-containing solution (a) into contact with the carrier under an alkaline condition; and an elution step (R2) of eluting the 226Ra ions from the carrier under an acidic condition.

Abstract: One embodiment of the present invention relates to a production method of a 226Ra target, a production method of 225Ac, or an electrodeposition solution for producing a 226Ra target, and the production method of a 226Ra target includes an electrodeposition step of electrodepositing a 226Ra-containing substance on a substrate by using an electrodeposition solution that contains 226Ra ions and a pH buffer.

Abstract: A method for producing 225A including: a method (X) for purifying a 226Ra-containing solution, including an adsorption step of allowing a 226Ra ion to adsorb onto a carrier having a function of selectively adsorbing a divalent cation by bringing a 226Ra-containing solution into contact with the carrier under an alkaline condition, and an elution step of eluting the 226Ra ion from the carrier under an acidic condition; a method for producing a 226Ra target, including an electrodeposition liquid preparation step of preparing an electrodeposition liquid by using a purified 226Ra-containing solution obtained by the method (X), and an electrodeposition step of electrodepositing a 226Ra-containing substance on a substrate by using the electrodeposition liquid; and a step of irradiating a 226Ra target produced by the method for producing a 226Ra target with at least one selected from a charged particle, a photon, and a neutron by using an accelerator.

Abstract: One embodiment of the present invention relates to a production method of 225Ac includes; a production step of a 226Ra target including an electrodeposition step of electrodepositing a 226Ra-containing substance on a substrate by using an electrodeposition solution that contains 226Ra ions and a pH buffer, and an irradiating step of irradiating the 226Ra target with at least one selected from charged particles, photons, and neutrons.

Abstract: A method for producing a radioactive metal complex includes a step of allowing a radioactive metal to react with DOTA or a derivative thereof as a ligand in a reaction liquid to form a radioactive metal complex. The reaction liquid contains water, a buffer, and a water-soluble organic solvent. The radioactive metal is 89Zr or 225Ac. The ligand may have, in the structure thereof, a group to which a peptide is linked. The content of the water-soluble organic solvent in the reaction liquid is preferably 2% by volume or more and 50% by volume or less. The radioactive metal is preferably allowed to react with the ligand in the reaction liquid at 30° C. or higher and 80° C. or lower.

Abstract: The RI-labeled anti-MUC5AC humanized antibody of the present invention is a conjugate of a chelating agent chelated with a radionuclide and an antibody (the radionuclide is a metal nuclide that emits ? particle or positron, and the antibody is a humanized antibody specifically binding to MUC5AC), and is superior in specificity for MUC5AC and accumulation in tumor. Therefore, it is extremely useful for the treatment and/or diagnosis of diseases in which MUC5AC is overexpressed, particularly cancer.

Abstract: Provided is a method for producing a radiohalogen-labeled compound, the method comprises: a step in which a radiohalogen-labeling precursor compound (S-L) having a leaving group (L) capable of being nucleophilically substituted by a radioactive halide ion (X?) is subjected to a radiohalogenation reaction to obtain a reaction mixture RM1 which contains the radiohalogen-labeling precursor compound (S-L) and a reaction product (S—X) resulting from the radiohalogenation reaction; a step in which the reaction mixture RM1 is mixed with a polyvalent acid or a salt thereof to obtain a reaction mixture RM2; and a step in which the reaction product (S—X) is purified from the reaction mixture RM2 by a solid phase extraction method.

Abstract: Provided are a compound represented by the following formula (1): wherein X1 represents a hydrogen atom or a halogen atom, X2 represents a fluorine atom or a nitrile group, and X3 represents a radioactive halogen atom, or a salt thereof, and a medicament including the same.

Abstract: Provided is a target transport system which is advantageous in simplifying and downsizing a configuration in production of radio-isotopes using an accelerator and in which components are hardly affected to be damaged by radiation. The target transport system includes: a transport pipeline through which a target body is transported; a target holding part that holds the target body and allows the target body to be irradiated with particle beams; and a pump, the transport pipeline, and a target entry port that transport the target body to the target holding part by a cooling water. The pump, the transport pipeline, and the target entry port cause the cooling water to flow in the transport direction, and the target body is recovered from the transport pipeline by the cooling water.

Abstract: The RI-labeled anti-MUC5AC humanized antibody of the present invention is a conjugate of a chelating agent chelated with a radionuclide and an antibody (the radionuclide is a metal nuclide that emits ? particle or positron, and the antibody is a humanized antibody specifically binding to MUC5AC), and is superior in specificity for MUC5AC and accumulation in tumor. Therefore, it is extremely useful for the treatment and/or diagnosis of diseases in which MUC5AC is overexpressed, particularly cancer.

Abstract: The present invention provides a radiolabeled compound represented by the following formula (1), which is a radioactive imidazothiadiazole derivative compound having an affinity for CA-IX, or a salt thereof. wherein n is an integer of 1 to 4, and L represents a radionuclide or a mono- to tetravalent group containing a radionuclide.

Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.

Abstract: The present invention relates to a labeling technique which can facilitate the metabolism in the liver after administration to patients without the reduction in the antibody function, thereby reducing accumulation of radionuclides in an organ such as the liver, and provides a modified antibody containing an IgG antibody and an IgG-binding peptide bound to the IgG antibody. The IgG-binding peptide has an amino acid sequence consisting of 13 to 17 amino acid residues, such as GPDCAYH(Xaa1)GELVWCTFH wherein Xaa1 represents a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, or diaminopropionic acid, and a compound represented by the following formula (II-1) is linked at a position of the lysine residue via a modification linker to the N terminus of the IgG-binding peptide.

Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.

Abstract: Provided are a compound represented by the following formula (1): wherein X1 represents a hydrogen atom or a halogen atom, X2 represents a fluorine atom or a nitrile group, and X3 represents a radioactive halogen atom, or a salt thereof, and a medicament including the same.

Abstract: There is provided a diagnostic imaging agent for early bone metastasis from cancer, containing trans-1-amino-[18F]fluorocyclobutanecarboxylic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: A simple method for producing a clinically applicable radiopharmaceutical composition containing 1-(2,2-dihydroxymethyl-3-[18F]fluoropropyl)-2-nitroimidazole ([18F]DiFA) or a salt thereof as an active ingredient, is provided which includes a synthesis step of obtaining a crude product of [18F]DiFA from a labeling precursor compound for [18F]DiFA; and a purification step of purifying the crude product, in which the purification step includes purifying [18F]DiFA using two or more different types of reverse phase solid phase extraction cartridges.

Abstract: Provided is a method for producing a radiohalogen-labeled compound, the method comprises: a step in which a radiohalogen-labeling precursor compound (S-L) having a leaving group (L) capable of being nucleophilically substituted by a radioactive halide ion (X?) is subjected to a radiohalogenation reaction to obtain a reaction mixture RM1 which contains the radiohalogen-labeling precursor compound (S-L) and a reaction product (S—X) resulting from the radiohalogenation reaction; a step in which the reaction mixture RM1 is mixed with a polyvalent acid or a salt thereof to obtain a reaction mixture RM2; and a step in which the reaction product (S—X) is purified from the reaction mixture RM2 by a solid phase extraction method.